NEW YORK (GenomeWeb) – BioTheranostics today said that it has received a positive coverage and reimbursement evaluation from a Medicare contractor for its Breast Cancer Index test.

Palmetto GBA, the Medicare administrator responsible for the MolDx molecular diagnostic technology assessment program, made the determination and the US Centers for Medicare and Medicaid Services posted the policy, according to the San Diego-based firm. BioTheranostics didn't disclose CMS pricing for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.